These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 36703939)
1. Upregulation of NDUFAF2 in Lung Adenocarcinoma Is a Novel Independent Prognostic Biomarker. Zou K; Gao P; Xu X; Zhang W; Zeng Z Comput Math Methods Med; 2023; 2023():2912968. PubMed ID: 36703939 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
3. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ Front Immunol; 2021; 12():724741. PubMed ID: 34335635 [TBL] [Abstract][Full Text] [Related]
4. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma. Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451 [TBL] [Abstract][Full Text] [Related]
5. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Gao P; Zou K; Xiao L; Zhou H; Xu X; Zeng Z; Zhang W Int Immunopharmacol; 2022 Sep; 110():108954. PubMed ID: 35820363 [TBL] [Abstract][Full Text] [Related]
6. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma. Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573 [TBL] [Abstract][Full Text] [Related]
7. Integrated analyzes identify CCT3 as a modulator to shape immunosuppressive tumor microenvironment in lung adenocarcinoma. Huang J; Hu B; Yang Y; Liu H; Fan X; Zhou J; Chen L BMC Cancer; 2023 Mar; 23(1):241. PubMed ID: 36918801 [TBL] [Abstract][Full Text] [Related]
8. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma. Chen R; Wang Z; Lu T; Liu Y; Ji Y; Yu Y; Tou F; Guo S Thorac Cancer; 2023 Apr; 14(10):893-912. PubMed ID: 36825773 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma. Liu W; Du Q; Mei T; Wang J; Huang D; Qin T BMC Cancer; 2024 Jan; 24(1):94. PubMed ID: 38233752 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics. Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308 [TBL] [Abstract][Full Text] [Related]
11. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689 [TBL] [Abstract][Full Text] [Related]
12. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma. Feng W; He Z; Shi L; Zhu Z; Ma H Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747 [TBL] [Abstract][Full Text] [Related]
13. Zheng X; Han L; Guan J; Chen C; Zhang Y; Zhang J; Zhang Y; Liu S; Su J; Liu M; Huang H Front Oncol; 2023; 13():1274439. PubMed ID: 38152367 [TBL] [Abstract][Full Text] [Related]
14. STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis. Zhang WD; Hu DM; Shi ZE; Wang QX; Zhang MY; Liu JY; Ji XL; Qu YQ Int J Med Sci; 2023; 20(11):1427-1447. PubMed ID: 37790851 [No Abstract] [Full Text] [Related]
15. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642 [TBL] [Abstract][Full Text] [Related]
16. H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation. Li Z; Hu M; Qiu J; Feng J; Zhang R; Wu H; Hu G; Ren J Med Sci Monit; 2022 Jan; 28():e933447. PubMed ID: 35027526 [TBL] [Abstract][Full Text] [Related]
17. Prognostic and immunological potential of PPM1G in lung adenocarcinoma. Yin R; Qu L; Wang Z; Tang J; Gu H; Wang X; Yang D; Du P; Dong M Mol Med Rep; 2023 Aug; 28(2):. PubMed ID: 37387407 [TBL] [Abstract][Full Text] [Related]
18. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Jing Y; Mao Z; Zhu J; Ma X; Liu H; Chen F Int Immunopharmacol; 2023 Sep; 122():110605. PubMed ID: 37451021 [TBL] [Abstract][Full Text] [Related]
19. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma. Ma C; Kang W; Yu L; Yang Z; Ding T Front Oncol; 2020; 10():590006. PubMed ID: 33363020 [TBL] [Abstract][Full Text] [Related]
20. CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma. Tan J; Chen F; Ouyang B; Li X; Zhang W; Gao X Front Oncol; 2022; 12():865756. PubMed ID: 36185189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]